Role of T-cell immunoglobulin and mucin domain-containing molecule 3 in the development and progression of liver diseases / 临床肝胆病杂志

T-cell immunoglobulin and mucin domain-containing molecule-3 （Tim-3） is a member of the Tim family and has been a research hotspot in recent years. As a negative regulatory factor， Tim-3 exerts different effects by binding to different ligands. Tim-3 is expressed in various types of immune cells， such as natural killer cells， dendritic cells， and monocytes， and Tim-3 has a regulatory effect on the functions of these immune cells. In recent years， a large number of studies have shown that Tim-3 is closely associated with the development and progression of liver diseases. This article reviews the studies on the role and mechanism of Tim-3 in different liver diseases and cells in recent years， in order to provide richer perspectives and ideas for the clinical diagnosis and treatment of liver diseases.

Mechanism of action of macrophage efferocytosis in acute and chronic liver diseases and related targeted therapy / 临床肝胆病杂志

Efferocytosis refers to the process by which apoptotic cells are engulfed and cleared by phagocytes， including professional phagocytes， such as macrophages and dendritic cells， and non-professional phagocytes， such as epithelial cells. Liver macrophages are the main cells with the function of efferocytosis in the liver. In recent years， an increasing number of studies have shown that various acute and chronic liver diseases are associated with the efferocytosis function of liver macrophages， including acute liver injury， alcoholic liver disease， nonalcoholic fatty liver disease， autoimmune liver disease， liver fibrosis， and liver cancer. This article elaborates on the expression of molecules associated with the efferocytosis function of macrophages， the process of efferocytosis， and the role of efferocytosis function in different liver diseases， so as to provide new ideas for the treatment of liver diseases.

Research advances in primary biliary cholangitis with dyslipidemia / 临床肝胆病杂志

Primary biliary cholangitis （PBC） is an autoimmune liver disease characterized by progressive and non-purulent inflammation of small- and medium-sized bile ducts in the liver. Recent studies have shown that abnormal lipid metabolism is relatively common in patients with PBC， and 76% of PBC patients have dyslipidemia. The effects and harms of dyslipidemia have attracted much attention. Lipid metabolism disorders play an important role in the progression of PBC. This article mainly reviews the research advances in the manifestation， role， diagnosis， and treatment of lipid metabolism disorders in PBC， so as to provide new ideas for the treatment of PBC.